| PRECLINICAL | evidence | Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study. | Semaglutide | — | 2026-07-23 |
| PRECLINICAL | evidence | Implications of Generic Semaglutide Availability on the Cost-Effectiveness of GLP-1RA for Guideline-Indicated Patients With Type 2 Diabetes. | Semaglutide | — | 2026-07-22 |
| PRECLINICAL | evidence | Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide. | Semaglutide | — | 2026-07-22 |
| PRECLINICAL | evidence | Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024. | Semaglutide | — | 2026-07-22 |
| PRECLINICAL | evidence | Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence. | Semaglutide | — | 2026-07-22 |
| PRECLINICAL | evidence | Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis. | Semaglutide | — | 2026-07-21 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans. | Semaglutide | — | 2026-07-21 |
| PRECLINICAL | evidence | Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes? | Semaglutide | — | 2026-07-21 |
| PRECLINICAL | evidence | From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists. | Semaglutide | — | 2026-07-21 |
| PRECLINICAL | evidence | Artificial intelligence as a new commercial determinant of health. | Semaglutide | — | 2026-07-21 |
| PRECLINICAL | evidence | Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study. | Semaglutide | Glycemic control | 2026-07-21 |
| PRECLINICAL | evidence | Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation. | Semaglutide | — | 2026-07-21 |
| PRECLINICAL | evidence | Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models. | Semaglutide | Inflammation | 2026-07-21 |
| PRECLINICAL | evidence | Thermosensitive hydrogels for sustained semaglutide release: overcoming weight loss plateau in diet-induced obese rats. | Semaglutide | — | 2026-07-20 |
| PRECLINICAL | evidence | Affordable Semaglutide in India: Expanding Access and Unanswered Questions for Children and Special Populations. | Semaglutide | — | 2026-07-20 |
| PRECLINICAL | evidence | Pre-operative concerns and post-operative satisfaction: comparing attitudes toward bariatric surgery and medication intervention for weight loss on Reddit. | Ozempic | — | 2026-07-20 |
| PRECLINICAL | evidence | Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations. | Semaglutide | — | 2026-07-20 |
| PRECLINICAL | evidence | Linking pediatric obesity to youth-onset type 2 diabetes: integrated longitudinal and cross-sectional evidence from population-based studies worldwide. | Semaglutide | — | 2026-07-20 |
| PRECLINICAL | evidence | Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk. | Semaglutide | — | 2026-07-20 |
| PRECLINICAL | evidence | Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial. | Semaglutide | — | 2026-07-19 |
| PRECLINICAL | evidence | Semaglutide promotes angiogenesis and blood-brain barrier repair after traumatic brain injury via PDGF-BB/PDGFRbeta/Ang1/Tie2/VEGF signaling pathway. | Semaglutide | — | 2026-07-18 |
| PRECLINICAL | evidence | Trends in Usage and Payments for Glucagon-Like Peptide-1 Receptor Agonists in the United States, 2017 to 2022: A Nationally Representative Repeated Cross-Sectional Study. | Semaglutide | — | 2026-07-17 |
| PRECLINICAL | evidence | Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide. | Semaglutide | — | 2026-07-17 |
| PRECLINICAL | evidence | Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series. | Semaglutide | — | 2026-07-17 |
| PRECLINICAL | evidence | Peripheral artery disease: advances in medical therapy. | Semaglutide | — | 2026-07-17 |
| PRECLINICAL | evidence | N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement. | Semaglutide | — | 2026-07-17 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications. | Semaglutide | — | 2026-07-17 |
| PRECLINICAL | evidence | The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice. | Semaglutide | — | 2026-07-16 |
| PRECLINICAL | evidence | Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data. | Semaglutide | — | 2026-07-16 |
| PRECLINICAL | evidence | Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use. | Semaglutide | — | 2026-07-16 |
| PRECLINICAL | evidence | Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk. | Semaglutide | — | 2026-07-15 |
| PRECLINICAL | evidence | Semaglutide and Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Fibrosis: An Exploratory Indirect Comparison. | Semaglutide | — | 2026-07-15 |
| PRECLINICAL | evidence | Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists. | Semaglutide | — | 2026-07-15 |
| PRECLINICAL | evidence | Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial. | Semaglutide | — | 2026-07-15 |
| PRECLINICAL | evidence | Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight. | Semaglutide | — | 2026-07-15 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder. | Semaglutide | Glycemic control | 2026-07-15 |
| PRECLINICAL | evidence | Redemptive narratives of remission: agency, free will and type 2 diabetes in the era of Ozempic. | Ozempic | — | 2026-07-14 |
| PRECLINICAL | evidence | Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation. | Semaglutide | — | 2026-07-14 |
| PRECLINICAL | evidence | On indirect negative inotropic effects of muscarine in the isolated human atrium. | Semaglutide | — | 2026-07-14 |
| PRECLINICAL | evidence | Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs. | Semaglutide | — | 2026-07-14 |
| PRECLINICAL | evidence | Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. | Semaglutide | — | 2026-07-14 |
| PRECLINICAL | evidence | Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation. | Semaglutide | Glycemic control | 2026-07-14 |
| PRECLINICAL | evidence | A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026. | Semaglutide | — | 2026-07-14 |
| PRECLINICAL | evidence | Revision Medialization Thyroplasty for Glottic Insufficiency Amid Rapid Weight Loss on Semaglutide. | Semaglutide | — | 2026-07-13 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists and Fertility: What Is Known So Far? | Semaglutide | — | 2026-07-13 |
| PRECLINICAL | evidence | Sustained metabolic control in latent autoimmune diabetes in adults (LADA) with semaglutide therapy in a patient with multiple autoimmune comorbidities: a case report and literature review. | Semaglutide | — | 2026-07-13 |
| PRECLINICAL | evidence | Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey. | Semaglutide | — | 2026-07-13 |
| PRECLINICAL | evidence | Comment on 'Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan'. | Semaglutide | — | 2026-07-13 |
| PRECLINICAL | evidence | How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access. | Semaglutide | — | 2026-07-12 |
| PRECLINICAL | evidence | TAAR1 as a Potential Alternate Molecular Target to GLP-1 for Novel Anti-diabetic, Anti-obesity Medications. | Semaglutide | — | 2026-07-11 |